ClinicalTrials.gg
RecruitingNCT07465107Ex-ParkUpdated Mar 11, 2026

Motor and Cognitive Exercise in Parkinson's Disease.

An interventional study of Motor-cognitive exercise and Usual Care in Parkinson Disease (PD), sponsored by Annemette Lokkegaard. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Annemette Lokkegaard · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Parkinson Disease with a site in Denmark — 12 open to participants now, 18 under way, 1 of them phase 3. Parkinson Disease · Denmark.

Planned enrollment
23rd of 33
48 · median 75
Started
2025
with 6 others
No phase
23 of 50
9 open now
Primary completion
2027-02
later than 8 of 17 live
Registered
42nd of 50
by date
Lead sponsor
1 of 50
Annemette Lokkegaard

Among the 50 studies in Parkinson Disease with a site in Denmark, this one is the 23rd largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2025, is one of 23 with no phase, reaches primary completion later than 8 of the 17 other live ones, and was the 42nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

12 of the 50 studies in Parkinson Disease with a site in Denmark are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Parkinson Disease with a site in Denmark, or all of them as a file.
02

Study summary

The aim of this study is to examine the effects of a specialized multi-modal intervention in patients with moderate to advanced Parkinson's disease (PD). The hypothesis is that a specialized motor- and cognitive exercise program in addition to usual care can improve gait and balance better than usual care alone.

48 patients with PD and a symptom duration of 4 or more years will be randomized 1:1 to either a control arm or to an intervention arm. The control arm will have usual management of their PD. The intervention arm will receive exercises aimed at both motor and cognitive impairments of PD over the course of 12 weeks.

The study has been designed in partnership with the Copenhagen Trial Unit (CTU), Copenhagen Univeristy Hospital, to ensure both internal and external validity. To increase reproducibility, detailed protocols for all training modalities will be shared along with the study results.

This study is a feasibility study with the intention of a following international multi-center study to corroborate the results. Both feasibility outcomes for the intervention itself and clinical outcomes for the participants will be published.

Read the detailed description

Intervention: The exercise program will consist of gait and balance training, lower body strength training and dual task training while treadmill walking. The program will include an individualized and progressive exercise program 3 times x 1 hour a week for 12 weeks with the following exercise modalities:

  1. Treadmill training for gait and balance training combined with dual task motor cognitive training.
  2. Progressive gait and motor-cognitive balance exercises
  3. Progressive resistance training including leg press.

The program will be conducted under supervision by a physiotherapist or an exercise physiologist. Usual treatment is permitted during the trial, both pharmacological and non-pharmacological. The treatment is preferably stable during the intervention and follow-up, but necessary changes will be registered.

All participants will be examined at baseline, after 12 weeks and again 6 and 12 months after baseline.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

Keywords

  • Parkinson Disease
  • Exercise Therapy
  • Gait
  • Balance
  • Motor-cognitive training
  • Dual-task
  • Neurological Rehabilitation
  • Psychomotor Performance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PD according to MDS-PD criteria
  • Aged ≥ 18 years
  • PD symptoms ≥ 4 years
  • Independent gait

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of PD Dementia according to the MDS-PD Dementia criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Control

    The control arm will continue usual management (best medical treatment) of their PD and other potentiel comorbidities at the discretion of their regular physician and other health providers. Enrollment in this study will not influence any clinical decisions or potential changes in management.

    Other: Usual Care

  • Experimental
    Intervention

    The intervention arm will receive 3 weekly 1-hour sessions of multi-modal training over the course of 12 weeks, totaling 36 sessions, in addition to usual management (best medical treatment). As with the control arm, any clinical decisions or potential changes in management will not be influenced be enrollment in this study.

    Other: Motor-cognitive exercise

Interventions

  • OtherMotor-cognitive exercise

    3 weekly 1-hour sessions of motor-cognitive exercise. Each 1-hour session will be multi-modal with 20 minutes of dynamic balance training, 20 minutes of dual-task exercises while treadmill walking and 20 minutes of lower body strength training with leg press. Detailed protocols for the exercises will be published along with results.

  • OtherUsual Care

    Best medical treatment: usual management of participants' PD and other potential comorbidities at the discretion of their regular physician and other health providers.

06

What researchers measure

Primary outcomes

  1. Feasibility: Intervention adherence

    Adherence defined as the proportion of participation in exercise sessions out of 36. A proportion of more than 60% will be considered acceptable.

    Time frame: From allocation to the end of 12 weeks of intervention (T2)

  2. Exploratory composite clinical outcome: Significant fall, all-cause hospitalization and all-cause mortality

    A composite outcome of either death, unplanned hospitalization or a significant fall. A significant fall will be defined as a fall leading to an unplanned hospital contact or contact with the general practitioner. This composite outcome is based on binary events that will be registered at each pre-specified follow-up time.

    Time frame: From enrollment to 1-year follow-up (T4)

Secondary outcomes

  1. Feasibility: Missing data (primary clinical outcome)

    Proportion of missing data on the exploratory primary clinical outcome "Significant fall, all-cause hospitalization and all-cause mortality". A proportion of less than 5% will be considered acceptable.

    Time frame: From enrollment to 6-month follow-up (T3)

  2. Feasibility: Missing data (secondary clinical outcomes)

    Proportion of missing data on the exploratory secondary clinical outcomes. A proportion of less than 10% will be considered acceptable.

    Time frame: At baseline (T1), end of intervention at 12 weeks (T2), follow-up at 6 months (T3) and follow-up at 1 year (T4).

  3. Feasibility: Randomization rate

    Screened compared to randomized. A rate of more than 70% randomized will be considered acceptable.

    Time frame: From screening to baseline, up to 1 year.

  4. Feasibility: Drop-out rate

    Drop-out at any time after enrollment. A drop-out of about 20 % is expected.

    Time frame: Through study completion, an average of 1 year

  5. Feasibility: Treatment fidelity

    Examination of attendance rate

    Time frame: Through study completion, an average of 1 year

Other outcomes

  1. Exploratory secondary clinical outcomes

    Hospital and institution free days

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  2. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  3. Montreal Cognitive Assessment (MoCA)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  4. Short Falls Efficacy Scale (Short-FES)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  5. Parkinson's Disease Questionnaire (PDQ-39)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  6. Mini Balance Evaluation Systems Test (Mini-BESTest)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  7. 30-second Chair Stand Test (30s-CST)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year

  8. Handgrip strength (HGS)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  9. Timed Up and Go (TUG)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  10. Physical activity, Diary

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  11. Falls, diary

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

  12. Dual-task interference (DTi)

    Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology, Bispebjerg and Frederiksberg Hospital
    Copenhagen NV, 2400, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 22 months is close to that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Mar 11, 2026
StartActual
Mar 26, 2025
Primary completionEst.
Feb 14, 2027
CompletionEst.
Feb 14, 2027
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07465107
Lead sponsor
Annemette Lokkegaard
Collaborators
Copenhagen Trial Unit, Center for Clinical Intervention Research
Responsible party
Annemette Lokkegaard (MD, PhD, Ass. Professor, Consultant Neurologist, University Hospital Bispebjerg and Frederiksberg) — Sponsor-investigator
First posted
Mar 11, 2026
Start date
Mar 26, 2025
Primary completion
Feb 14, 2027 (estimated)
Completion
Feb 14, 2027 (estimated)
Last update
Mar 11, 2026

Study contacts

Annemette Løkkegaard, MD, PhD
Contact
annemette.loekkegaard@regionh.dk
+45 38 63 52 48
Løkkegaard
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion